Solifenacin
- Atc Codes:G04BD08
- CAS Codes:242478-38-2#242478-37-1
- PHARMGKB ID:242478-38-2#242478-37-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Vesicare; Belgium: Vesicare; Bulgaria: Vesicare; Cyprus: Vesicare; Czech Republic: Vesicare; Denmark: Vesicare; Estonia: Vesicare; Finland: Vesicare; France: Vesicare; Germany: Vesicare, Vesikur; Greece: Vesicare; Hungary: Vesicare; Italy: Vesiker; Latvia: Vesicare; Lithuania: Vesicare; Luxembourg: Vesicare; Malta: Vesicare; Netherlands: Flomin, Uriclin, Vesicare; Poland: Vesicare; Portugal: Flomin, Uriclin, Vesicare; Romania: Vesicare; Slovakia: Vesicare; Slovenia: Vesicare; Spain: Vesicare; Sweden: Vesicare; UK: Vesicare.
North America
Canada: Vesicare; USA: Vesicare.
Latin America
Argentina: Vesicare; Mexico: Vesicare.
Asia
Japan: Vesicare.
Drug combinations
Chemistry
Solifenacin Succinate: C~23~H~26~N~2~O~2~ C~4~H~6~O~4~. Mw: 480.55. Butanedioic acid, cmpd. with (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1). CAS-242478-38-2; CAS-242478-37-1 (solifenacin)(2001).
Pharmacologic Category
Genitourinary Smooth Muscle Relaxants. Anticholinergic Agent. (ATC-Code: G04BD08).
Mechanism of action
Potent and selective antimuscarinic agent. Shows specific binding for muscarinic M~3~ receptors in vitro and functional selectivity for urinary bladder over secretory (e.g. salivary) glands. Inhibits contraction of detrusor muscle of bladder, resulting in decreased bladder activity.
Therapeutic use
Overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence.
Pregnancy and lactiation implications
Decreased fetal weight, increased incidence of cleft palate, and delayed physical development observed in animals. There are no adequate studies in pregnant women. Use during pregnancy only if benefit to mother outweighs potential risk to fetus. Excretion in breast milk unknown (not recommended in nursing women).
Unlabeled use
Contraindications
Hypersensitivity to solifenacin or any component of the formulation. Urinary retention. Gastric retention. Uncontrolled narrow-angle glaucoma.
Warnings and precautions
May cause drowsiness and/or blurred vision. Heat prostration may occur in presence of increased environmental temperature. Use with caution in bladder outflow obstruction (risk of urinary retention), in gastrointestinal obstructive disorders or decreased gastrointestinal motility, in controlled narrow-angle glaucoma (contraindicated in uncontrolled narrow-angle glaucoma), and in moderate hepatic impairment (use not recommended in patients with severe hepatic impairment). Use with caution in known history of QT prolongation or other risk factors for QT prolongation, and in renal impairment.